Acceleron Pharma, Inc.

Acceleron Pharma Announces Global Collaboration with Celgene Corporation on ACE-011 Program for Cancer-Related Bone Loss

Acceleron Pharma Announces Global Collaboration with Celgene Corporation on ACE-011 Program for Cancer-Related Bone Loss

February 20, 2008

CAMBRIDGE, Mass. & SUMMIT, N.J.--(BUSINESS WIRE)--Acceleron Pharma, Inc. and Celgene Corporation today announced a worldwide strategic collaboration for the joint development and commercialization of ACE-011, a first-in-class, novel bone-forming compound. The collaboration combines both companies’ resources and commitment to developing products for the treatment of cancer and cancer-related bone loss. In pre-clinical and early clinical studies, this innovative compound has reported success in key biomarkers of bone formation.

Selventa

Genstruct Announces New Collaboration with Pfizer in Drug Safety

Genstruct Announces New Collaboration with Pfizer in Drug Safety

February 20, 2008

CAMBRIDGE, Mass. February 20, 2008 – Genstruct Inc., a systems biology company focused on identifying molecular mechanisms, networks and biomarkers to better understand large scale biology announced today that it has entered into a Master Research Agreement with Pfizer designed to cover current and future collaborations. The first collaboration under this new agreement is in the area of preclinical drug safety, focusing initially on a systems biology analysis of underlying mechanisms of drug-induced liver injury.

Helicos BioSciences Corporation

Helicos BioSciences Announces Shipment of the World's First Single Molecule DNA Sequencer

Helicos BioSciences Announces Shipment of the World's First Single Molecule DNA Sequencer

March 5, 2008

First customer shipment marks a major inflection point in Genomic Analysis and a significant step toward the $1,000 Genome

BG Medicine, Inc.

Takeda Joins the HRP Initiative to Discover Biomarkers of High-Risk Atherosclerotic Plaque

Takeda Joins the HRP Initiative to Discover Biomarkers of High-Risk Atherosclerotic Plaque

April 1, 2008

Collaborative venture is focused on identifying individuals at high risk of heart attack or stroke to facilitate drug development and enabling the rapid discovery and development of new treatments that can prevent the first event.

Helicos BioSciences Corporation

Helicos BioSciences Announces Single Molecule DNA Sequence Data Published in Science Magazine

Helicos BioSciences Announces Single Molecule DNA Sequence Data Published in Science Magazine

April 3, 2008

Data Validates the World's First Single Molecule Sequencing of an Organism

Tetraphase Pharmaceuticals, Inc.

Tetraphase Pharmaceuticals Announces Appointment of Guy Macdonald as President and Chief Executive Officer

Tetraphase Pharmaceuticals Announces Appointment of Guy Macdonald as President and Chief Executive Officer

April 9, 2008

Industry Veteran to Lead Advancement of Company’s Breakthrough, Synthetic Chemistry Platform

VisEn Medical, Inc.

VisEn Medical Launches FMT™ 2500 – Next-Generation Fluorescence Imaging System

VisEn Medical Launches FMT™ 2500 – Next-Generation Fluorescence Imaging System

April 14, 2008

New Instrument Generates Real-Time In Vivo Data via Quantitative Tomography

VisEn Medical, Inc.

VisEn Medical Raises $5.0 Million in Expanded Series B Financing

VisEn Medical Raises $5.0 Million in Expanded Series B Financing

April 18, 2008

Woburn, MA, April 18, 2008 -- VisEn Medical, Inc., a leader in fluorescence in vivo imaging, today announced the expansion of its Series B financing. Merck Capital Ventures and Flagship Ventures co-led this $5.0 million expansion of the Series B round, which initially raised $7 million in November 2007, bringing the total Series B financing amount to $12.0 million. VisEn will use the additional financing to further advance its proprietary fluorescence in vivo imaging product pipelines, and to expand its commercial applications and customer support of its marketed products worldwide.

Resolvyx Pharmaceuticals, Inc.

Resolvyx Pharmaceuticals Strengthens Its Board of Directors with Industry Leaders

Resolvyx Pharmaceuticals Strengthens Its Board of Directors with Industry Leaders

April 22, 2008

BEDFORD, Mass.--(BUSINESS WIRE)--Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced the appointment of Timothy J. Barberich and George M. Milne, Jr., Ph.D, to Resolvyx's Board of Directors. Resolvyx is focused on developing drugs based on resolvins, a recently discovered family of naturally-occurring, small molecule lipid mediators that actively resolve inflammation and can be targeted to treat a wide range of diseases, including asthma, cardiovascular disease and multiple eye diseases.

Resolvyx Pharmaceuticals, Inc.

Resolvyx Pharmaceuticals Raises $25 Million in Series B Financing

Resolvyx Pharmaceuticals Raises $25 Million in Series B Financing

April 22, 2008

Company Advancing Resolvin Therapeutics to Initiate Human Clinical Trials in 2008